Loading
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Stock: price and insider trades · China
ST诺泰
No insider purchase over the last 90 days. The latest, by 刘婷, was filed 11 Mar 2025.
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.: what insiders have been doing
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Between 18 October 2025 and 18 October 2026, 1 insider published 1 filing.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €34k. Biggest ticket of the year: €34k, sold by 林浩 and made public on 14 July 2026.
Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (515 companies, median 2 filings), a count of 1 filing is below the norm. Over the whole record (from 2022), the tally stands at 1 purchase and 6 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€2,544
1 ops. · all time
Sell Volume
€796,277
6 ops. · all time
Who traded when
BuySale刘婷1 buy2 sales
林浩2 sales
Since the insiders bought
- -14.7%Entry CN¥38.26 · Close at T+365 CN¥32.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,731 of 23,476 companies
49.2
score / 100
Value36
Quality62
FCF yld-7.7%
Earn yld3.7%
EV/EBITDA15.5x
ROE7.7%
Gross mgn63%
Net mgn17%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥28.21
Analyst consensus
Income statement
RevenueCN¥1.9B
Gross profitCN¥1.2B63% margin
EBITDACN¥743.9M38% margin
Net incomeCN¥332.4M11.7% margin
Valuation
PER (trailing)37.6x
P/Book2.9x
Beta0.31
Balance sheet & cash
Market capCN¥8.9B
Total debtCN¥2.7B
Free Cash Flow-CN¥685.8M
Debt / Equity91%
Profitability & ownership
ROE7.7%
ROA4.3%
% insiders44.4%
% institutions0.5%
Last declaration on 14 July 2026
Declarations7 total
74,092 shares100.0% of flowA股XSHGSSE:173000007356399260
7 of 7 declarations
About Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.
ST诺泰 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on the development and commercialization of innovative pharmaceutical products.
